Welcome to our dedicated page for Picard Medical news (Ticker: PMI), a resource for investors and traders seeking the latest updates and insights on Picard Medical stock.
Picard Medical, Inc. (NYSE American: PMI) is the parent company of SynCardia Systems, LLC, a medical technology company focused on total artificial heart therapy for patients with advanced and end-stage heart failure. News about Picard Medical often centers on the SynCardia Total Artificial Heart (STAH), which company materials describe as the only commercially available total artificial heart technology for patients with end-stage heart failure and the first artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada.
Readers of this PMI news page can expect coverage of clinical and technology milestones related to the SynCardia Total Artificial Heart and the next-generation, fully implantable Emperor Total Artificial Heart platform. Recent company announcements have highlighted in vitro and in vivo data on the Emperor system, including the first pre-clinical implantations of the fully implantable device, as well as presentations at specialized heart failure and mechanical circulatory support conferences.
Picard Medical’s news flow also includes updates on product enhancements, such as the rollout of FDA-cleared CPC1 Connector Covers designed to provide additional protection and comfort for patients using the SynCardia Total Artificial Heart. Corporate and capital markets developments, including senior secured debt financings, registration statements, and participation in healthcare investor conferences, are disclosed through press releases and corresponding SEC filings.
Investors and clinicians following PMI news can use this page to review company communications on regulatory developments, collaboration agreements for the Emperor platform, clinical data presentations, and broader strategic updates related to total artificial heart technology. The news archive offers a consolidated view of how Picard Medical and SynCardia are advancing their artificial heart platforms and engaging with the heart failure and medical device communities.
Picard Medical (NYSE American: PMI) recognized Banner Health for performing more than 50 SynCardia Total Artificial Heart (STAH) implants, marking one of the busiest global programs in bridge-to-transplant therapy. The release notes >2,100 STAH implants worldwide and ongoing development of a fully implantable Emperor Total Artificial Heart.
The announcement highlights Banner’s role in clinical practice development across patient selection, surgical technique, and post-implant management for advanced biventricular heart failure.
Picard Medical (NYSE American: PMI) and SynCardia were featured in a two-part interview series with Joe Mullings that highlights total artificial heart therapy, the advanced heart failure market, and the company’s next‑generation platform development. Picard Medical CEO Patrick N.J. Schnegelsberg discusses SynCardia clinical use and the fully implantable Emperor Total Artificial Heart.
Picard Medical (NYSE American: PMI) reported preliminary, unaudited Q1 2026 revenue of $1.1 million, up 79.9% from $0.6 million a year earlier, driven by higher SynCardia Total Artificial Heart utilization and increased driver rental pricing and income.
The company cautioned the figures are preliminary and unaudited and expects to file its Form 10-Q on or before May 15, 2026.
Picard Medical (NYSE American: PMI) will present SynCardia’s next-generation total artificial heart platform at ISHLT 2026 in Toronto on April 24, 2026. The poster, titled “The Emperor Total Artificial Heart: A Fully Implantable Solution for End Stage Heart Failure”, highlights ongoing development of a fully implantable TAH.
SynCardia will also exhibit at booth 409, offering clinicians and attendees information on the SynCardia Total Artificial Heart and efforts to expand access to life‑sustaining therapies.
Picard Medical (NYSE American: PMI) highlighted use of the SynCardia Total Artificial Heart (STAH) as a bridge to transplant at Texas Children’s Hospital for a 21-year-old re-transplant patient.
The patient was supported on the STAH for approximately two and a half months before receiving a donor heart and subsequent successful transplant and discharge. The STAH replaces both ventricles for end-stage biventricular failure; Picard is also developing the fully implantable Emperor Total Artificial Heart.
Picard Medical (NYSE American: PMI) announced that SynCardia COO Matt Schuster will deliver a keynote at Venture Café Phoenix during Arizona Tech Week on April 9, 2026, 6:20–6:40 p.m. at the Phoenix Bioscience Core CEI Main Stage.
The keynote will highlight next‑generation fully implantable total artificial heart technology, efforts to expand access for women with advanced heart failure, and recent clinical experience at leading transplant centers including UCSF.
Picard Medical (NYSE American: PMI) and SynCardia will participate in a Voice of the Patient event during AZ Tech Week on April 9, 2026 in Tucson.
The program spotlights patient experiences with advanced heart failure care, featuring clinicians, a SynCardia implanting surgeon, and a patient speaker.
Picard Medical (NYSE American: PMI) reported 2025 results showing revenue growth, improved operating performance, and a stronger balance sheet after its public listing. Revenue was $4.94 million, up 12.5% year-over-year; cash totaled $11.5 million versus $0.1 million at year-end 2024.
Product revenue was $4.75 million; gross margin remained negative at (4.1%). Net loss widened to $(27.0) million, while operating loss improved slightly to $(13.3) million. The company raised net proceeds from equity and debt financings during 2025 and said additional capital will be required.
Picard Medical (NYSE: PMI) will present early preclinical data for its next‑generation Emperor Total Artificial Heart at the American College of Cardiology Annual Scientific Session (ACC.26) in New Orleans, March 28–30, 2026.
The poster, titled THE EMPEROR TOTAL ARTIFICIAL HEART, is scheduled for March 29, 2026 at 11:00 a.m., and SynCardia will also staff exhibit booth #2554 to discuss the fully implantable, autoregulating electromechanical heart platform and related development plans.
Picard Medical (NYSE American: PMI) highlighted a UCSF Health case in which a patient in his twenties was supported on the SynCardia Total Artificial Heart for 119 days before a successful heart transplant on March 14, 2026.
This is the second of five UCSF patients bridged to transplant with the device, which is approved by the U.S. FDA and Health Canada, underscoring growing clinical adoption for advanced biventricular heart failure.